[Federal Register Volume 72, Number 31 (Thursday, February 15, 2007)]
[Rules and Regulations]
[Pages 7348-7349]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-2580]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522


Implantation or Injectable Dosage Form New Animal Drugs; 
Trenbolone Acetate and Estradiol

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a new animal drug application 
(NADA) filed by Intervet, Inc. The NADA provides for use of an 
additional dose of trenbolone acetate and estradiol implant used for 
increased

[[Page 7349]]

rate of weight gain and improved feed efficiency in feedlot steers.

DATES: This rule is effective February 15, 2007.

FOR FURTHER INFORMATION CONTACT: Eric S. Dubbin, Center for Veterinary 
Medicine (HFV-126), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-827-0232, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: Intervet, Inc., P.O. Box 318, 29160 Intervet 
Ln., Millsboro, DE 19966, filed NADA 141-269 that provides for REVALOR 
XS (trenbolone acetate and estradiol), an ear implant, used for 
increased rate of weight gain and improved feed efficiency in steers 
fed in confinement for slaughter. The supplemental NADA is approved as 
of January 19, 2007, and the regulations are amended in Sec.  522.2477 
(21 CFR 522.2477) to reflect the approval. The basis of approval is 
discussed in the freedom of information summary.
    In addition, FDA is revising the regulations in Sec.  522.2477 to 
correctly reflect products approved for another sponsor. This action is 
being taken to improve the accuracy of the regulations.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 
3 years of marketing exclusivity beginning January 19, 2007.
    FDA has determined under 21 CFR 25.33(a)(1) that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 522

    Animal drugs.


0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under the 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is 
amended as follows:

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 522 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. In Sec.  522.2477, revise paragraphs (b)(1), (b)(2), and (b)(3); and 
add paragraph (d)(1)(i)(G) to read as follows:


Sec.  522.2477  Trenbolone acetate and estradiol.

    (b) * * *
    (1) No. 021641 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B), 
(d)(1)(i)(C), (d)(1)(i)(D), (d)(1)(i)(E), (d)(1)(i)(F), (d)(1)(ii), 
(d)(1)(iii), (d)(2), and (d)(3) of this section.
    (2) No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(C), 
(d)(1)(i)(D), (d)(1)(i)(G), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), 
(d)(2)(i)(C), (d)(2)(i)(D), (d)(2)(ii), (d)(2)(iii), (d)(3)(i)(A), 
(d)(3)(ii), and (d)(3)(iii) of this section.
    (3) No. 000856 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(D), 
(d)(1)(ii), (d)(1)(iii), (d)(3)(i)(A), (d)(3)(ii), and (d)(3)(iii) of 
this section.
    (d) * * *
    (1) * * *
    (i) * * *
    (G) 200 milligram (mg) trenbolone acetate and 40 mg estradiol (one 
implant consisting of 10 pellets, each pellet containing 20 mg 
trenbolone acetate and 4 mg estradiol) per implant dose.

    Dated: February 6, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7-2580 Filed 2-14-07; 8:45 am]
BILLING CODE 4160-01-S